Global Survey Finds CROs Undergoing Major Changes to Speed Clinical Trials
29.10.2019 19:35:00 EET | Business Wire | Press release
Contract research organizations (CROs) are making significant progress in advancing the industrywide move to improve clinical trial performance, according to the Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report, one of the largest-ever surveys of clinical operations professionals globally. The findings from Veeva Systems (NYSE:VEEV) reveal that CROs are eliminating manual processes and modernizing key areas of clinical trial execution to enhance partner collaboration and improve study performance.
Streamlining Trial Collaboration
All CROs surveyed cite the need to streamline information exchange among study partners. Today, CROs share trial data and documents with sponsors and sites in multiple ways, many of which are manual. Email is CROs’ primary method to exchange information with sites and sponsors, and most still use paper shipments and file shares.
CROs say the state of information exchange causes major challenges with tracking and reporting (71%), misfiled or missing documents (59%), and a host of other issues that limit collaboration and compliance.
As a result, CROs are initiating change to simplify information exchange with study partners, which they expect to yield significant benefits, including reduction in manual processes (77%), streamlined collaboration (65%), improved study quality (64%), and faster study execution (64%).
Accelerating Study Start-up
Study start-up is one of the most resource-intensive phases of clinical trials and has the most opportunity to drive greater efficiency and speed. All CROs report significant challenges with study start-up and more than three-quarters use spreadsheets to manage this area.
Site contracting and budgeting is the most cited and fastest growing issue during the study start-up process. The majority of CROs (70%) say it is their top challenge, up 11 percentage points since 2018. It is also among the primary drivers for change.
For most (80%), faster study start-up time is also a primary driver. Majorities say fewer spreadsheets and manual processes (60%), easier collaboration with sponsors and sites (55%), and better resource planning (55%) would also speed the study start-up process.
Increasing Adoption of Advanced Clinical Applications
CROs are adopting more clinical technologies to eliminate manual processes and improve operational performance. The use of RTSM, eTMF, and CTMS systems has increased the most since 2017. In addition, more CROs are adopting purpose-built study start-up applications than sponsors to speed cycle times (35% of CROs vs. 23% of sponsors).
Replacing manual processes with technology for specific functions has created efficiencies, but it has also created silos. Integration (73%) and reporting across multiple applications (64%) are the top two challenges reported as a result of application silos.
CROs cite the need to streamline fragmented clinical processes and systems to improve study execution. All CROs say they need to unify clinical applications (100%). Better visibility and oversight (74%), faster trials (68%), and easier stakeholder collaboration (63%) are the top drivers to unify.
“CROs are leading the industrywide drive to improve execution and collaboration for faster clinical trials,” said Jim Reilly, vice president of Vault Clinical. “As more organizations reduce the manual and fragmented processes that are prevalent today, drug development will become much more streamlined and study partners will improve how they work together throughout the course of a trial.”
The Veeva 2019 Unified Clinical Operations Survey Report: Annual CRO Report examines CROs’ progress toward a unified clinical operating environment by gathering the experiences and opinions of CRO respondents from around the world. This annual research details the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry’s progress toward unifying clinical systems and processes and aligning stakeholders throughout study execution. The full report is available online at veeva.com/eu/CROreport.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 775 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
® 2019 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005858/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 03:00:00 EEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY ® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 02:58:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform the future for people living with sickle cell disease and transfusion-dependent beta thalassemia. The remarkable consistency of results across age groups reinforces the potential of CASGEVY to deliver durable, transformative benefits to those who have historically had limited options,” said Reshma Kewalramani, M.D., Chief Executive Officer and President, Vertex. “We’re deeply grateful to the patients, families and investigators who pa
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 22:15:00 EEST | Press release
Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. Lenders and borrowers compete in real time, helping create more efficient markets and enabling financial products with better rates and terms for users. USDG supplied through Robinhood Earn is deposited into a Morpho Vault
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 21:33:00 EEST | Press release
SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leaders every year. “The Prism Awards are recognized across the optics and photonics industry
Around 500 Attend Sino-European ESG Conference in Germany1.7.2026 19:00:00 EEST | Press release
Around 500 government officials, business executives and academics from China and Europe gathered in the western German city of Mainz on Friday for the Third Sino-European Corporate ESG Best Practice Conference to discuss how deeper cooperation can support sustainable economic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701255421/en/ Group photo of selected attendees at the conference. Hosted by the Chinese Consulate General in Frankfurt and jointly organized with authorities from Germany and China, the conference brought together participants from China, Germany, France, Italy, the Netherlands, Denmark, Luxembourg and several other countries under the theme "From Vision to Practice: Empowering Sustainable Growth Through Collaboration." Francesco La Camera, Director-General of the International Renewable Energy Agency (IRENA), delivered a video address. Speaking at the opening ceremony, Huang Yiyang, Chinese Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
